Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Nat Med Retrieve available abstracts of 51 articles: HTML format

Single Articles

August 2026
1. TIAN R, Zong X, Ren D, Tica S, et al
   Biological aging and generational shifts in early-onset cancer risk.
   Nat Med. 2026;32:2983-2990.
   PubMed     Abstract available
   
   
   June 2026
2. BYERS LA, Cho BC, Cooper AJ, Chiang AC, et al
   Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
   Nat Med. 2026 Jun 29. doi: 10.1038/s41591-026-04544.
   PubMed    
   
   
   
3. HUANG Z, Zeng L, Ruan Z, Zeng Q, et al
   Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
   Nat Med. 2026 Jun 24. doi: 10.1038/s41591-026-04508.
   PubMed    
   
   
   
4. KIM YW, Park EJ, Kwak KI, Yoon TH, et al
   Electronic cigarette use after smoking cessation and lung cancer risk.
   Nat Med. 2026 Jun 8. doi: 10.1038/s41591-026-04469.
   PubMed     Abstract available
   
   
   
5. BYERS LA, Cho BC, Cooper AJ, Chiang AC, et al
   SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
   Nat Med. 2026 Jun 1. doi: 10.1038/s41591-026-04452.
   PubMed     Abstract available
   
   
   
6. DING DY, Bot VA, Chen KL, Groves JW, et al
   Plasma proteomic signatures of cellular aging predict human disease.
   Nat Med. 2026;32:2060-2072.
   PubMed     Abstract available
   
   
   
7. TROST F, Zhang B, Aring I, Bauer M, et al
   An agentic framework for autonomous scientific discovery in cancer pathology.
   Nat Med. 2026;32:2254-2266.
   PubMed     Abstract available
   
   
   March 2026
8. CHO BC, Balaraman R, Chen HJ, Yu X, et al
   Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
   Nat Med. 2026 Mar 27. doi: 10.1038/s41591-026-04323.
   PubMed     Abstract available
   
   
   
9. WOZNITZA N, Smith L, Rawlinson J, Au-Yong I, et al
   AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.
   Nat Med. 2026 Mar 24. doi: 10.1038/s41591-026-04253.
   PubMed     Abstract available
   
   
   
10. LEE RW, Nair A, Balata H, Graham C, et al
    Implementation of the NHS England Lung Cancer Screening Programme over 5 years.
    Nat Med. 2026 Mar 23. doi: 10.1038/s41591-026-04292.
    PubMed     Abstract available
    
    
    February 2026
11. HUANG Z, Zeng L, Ruan Z, Zeng Q, et al
    Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
    Nat Med. 2026 Feb 2. doi: 10.1038/s41591-025-04181.
    PubMed     Abstract available
    
    
    January 2026
12. DUTTAGUPTA S, Messaoudene M, Hunter S, Desilets A, et al
    Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
    Nat Med. 2026 Jan 28. doi: 10.1038/s41591-025-04186.
    PubMed     Abstract available
    
    
    
13. LI Z, Li Y, Xiang J, Wang X, et al
    AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer.
    Nat Med. 2026 Jan 5. doi: 10.1038/s41591-025-04060.
    PubMed     Abstract available
    
    
    
14. ZHAO H, Bai Y, Chen L, Ma J, et al
    Generative AI-based low-dose digital subtraction angiography for intra-operative radiation dose reduction: a randomized controlled trial.
    Nat Med. 2026;32:288-296.
    PubMed     Abstract available
    
    
    December 2025
15. REUSS JE, Lee PK, Mehran RJ, Hu C, et al
    Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
    Nat Med. 2025;31:4097-4108.
    PubMed     Abstract available
    
    
    November 2025
16. LOVLY CM, McDonald NT, Chen H, Ortiz-Cuaran S, et al
    Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
    Nat Med. 2025 Nov 20. doi: 10.1038/s41591-025-04116.
    PubMed    
    
    
    August 2025
17. HONG S, Wang Q, Cheng Y, Luo Y, et al
    First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.
    Nat Med. 2025 Aug 19. doi: 10.1038/s41591-025-03883.
    PubMed     Abstract available
    
    
    
18. PREUSSER M, Garde-Noguera J, Garcia-Mosquera JJ, Gion M, et al
    Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.
    Nat Med. 2025;31:2797-2805.
    PubMed     Abstract available
    
    
    
19. CHO BC, Lu S, Lee MA, Song Z, et al
    D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial.
    Nat Med. 2025;31:2768-2777.
    PubMed     Abstract available
    
    
    July 2025
20. CAMPANELLA G, Kumar N, Nanda S, Singi S, et al
    Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection.
    Nat Med. 2025 Jul 9. doi: 10.1038/s41591-025-03780.
    PubMed     Abstract available
    
    
    
21. ZHOU C, Dong X, Chen G, Wang Z, et al
    Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.
    Nat Med. 2025;31:2375-2384.
    PubMed     Abstract available
    
    
    June 2025
22. MA Y, Yang Y, Huang Y, Fang W, et al
    A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
    Nat Med. 2025;31:1949-1957.
    PubMed     Abstract available
    
    
    May 2025
23. CASCONE T, Bonanno L, Guisier F, Insa A, et al
    Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
    Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03746.
    PubMed     Abstract available
    
    
    
24. SKOULIDIS F, Li BT, de Langen AJ, Hong DS, et al
    Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated non-small-cell lung cancer.
    Nat Med. 2025 May 28. doi: 10.1038/s41591-025-03732.
    PubMed     Abstract available
    
    
    
25. ZHENG MM, Zhou Q, Chen HJ, Jiang BY, et al
    Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases.
    Nat Med. 2025;31:1547-1556.
    PubMed     Abstract available
    
    
    April 2025
26. ZHAO S, Cheng Y, Wang Q, Li X, et al
    Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.
    Nat Med. 2025 Apr 10. doi: 10.1038/s41591-025-03638.
    PubMed     Abstract available
    
    
    March 2025
27. HERBST RS, John T, Grohe C, Goldman JW, et al
    Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
    Nat Med. 2025 Mar 17. doi: 10.1038/s41591-025-03577.
    PubMed     Abstract available
    
    
    February 2025
28. TAGORE S, Caprio L, Amin AD, Bestak K, et al
    Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases.
    Nat Med. 2025 Feb 27. doi: 10.1038/s41591-025-03530.
    PubMed     Abstract available
    
    
    January 2025
29. SHI Y, Fang J, Xing L, Yao Y, et al
    Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial.
    Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03401.
    PubMed     Abstract available
    
    
    
30. BLACK JRM, Bartha G, Abbott CW, Boyle SM, et al
    Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.
    Nat Med. 2025;31:70-76.
    PubMed     Abstract available
    
    
    
31. ZUCCATO JA, Mamatjan Y, Nassiri F, Ajisebutu A, et al
    Prediction of brain metastasis development with DNA methylation signatures.
    Nat Med. 2025;31:116-125.
    PubMed     Abstract available
    
    
    November 2024
32. ALBAN TJ, Riaz N, Parthasarathy P, Makarov V, et al
    Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.
    Nat Med. 2024;30:3209-3222.
    PubMed     Abstract available
    
    
    
33. WANG C, Shao J, He Y, Wu J, et al
    Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.
    Nat Med. 2024;30:3184-3195.
    PubMed     Abstract available
    
    
    September 2024
34. LI N, Wang SY
    Navigating treatment combinations in small-cell lung cancer.
    Nat Med. 2024 Sep 18. doi: 10.1038/s41591-024-03255.
    PubMed    
    
    
    
35. JEE J, Brannon AR, Singh R, Derkach A, et al
    DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.
    Nat Med. 2024;30:2499-2507.
    PubMed     Abstract available
    
    
    August 2024
36. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
    Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Nat Med. 2024 Aug 20. doi: 10.1038/s41591-024-03178.
    PubMed    
    
    
    July 2024
37. CHENG Y, Chen J, Zhang W, Xie C, et al
    Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
    Nat Med. 2024 Jul 11. doi: 10.1038/s41591-024-03132.
    PubMed     Abstract available
    
    
    June 2024
38. PETERS S, Gadgeel SM, Mok T, Nadal E, et al
    Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
    Nat Med. 2024 Jun 19. doi: 10.1038/s41591-024-03008.
    PubMed     Abstract available
    
    
    
39. WIDMAN AJ, Shah M, Frydendahl A, Halmos D, et al
    Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
    Nat Med. 2024;30:1655-1666.
    PubMed     Abstract available
    
    
    May 2024
40. SHIELDS MD, Lovly CM
    Refining neoadjuvant immunotherapy for resectable lung cancer.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-03001.
    PubMed    
    
    
    
41. ZENG Y, Hu CH, Li YZ, Zhou JS, et al
    Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02929.
    PubMed     Abstract available
    
    
    April 2024
42. SCHULER M, Cuppens K, Plones T, Wiesweg M, et al
    Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
    Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02965.
    PubMed     Abstract available
    
    
    
43. TAMMEMAGI MC, Darling GE, Schmidt H, Walker MJ, et al
    Risk-based lung cancer screening performance in a universal healthcare setting.
    Nat Med. 2024;30:1054-1064.
    PubMed     Abstract available
    
    
    
44. VAIDYA A, Chen RJ, Williamson DFK, Song AH, et al
    Demographic bias in misdiagnosis by computational pathology models.
    Nat Med. 2024;30:1174-1190.
    PubMed     Abstract available
    
    
    
45. SINGHAL A, Li BT, O'Reilly EM
    Targeting KRAS in cancer.
    Nat Med. 2024;30:969-983.
    PubMed     Abstract available
    
    
    
46. GHILARDI G, Fraietta JA, Gerson JN, Van Deerlin VM, et al
    T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
    Nat Med. 2024;30:984-989.
    PubMed     Abstract available
    
    
    February 2024
47. BESSE B, Pons-Tostivint E, Park K, Hartl S, et al
    Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Nat Med. 2024 Feb 13. doi: 10.1038/s41591-024-02808.
    PubMed     Abstract available
    
    
    October 2023
48. DEUTSCH JS, Cimino-Mathews A, Thompson E, Provencio M, et al
    Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
    Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660.
    PubMed     Abstract available
    
    
    
49. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
    Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
    Nat Med. 2023 Oct 10. doi: 10.1038/s41591-023-02627.
    PubMed    
    
    
    
50. ANAGNOSTOU V, Ho C, Nicholas G, Juergens RA, et al
    ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
    Nat Med. 2023 Oct 9. doi: 10.1038/s41591-023-02598.
    PubMed     Abstract available
    
    
    September 2023
51. CHO BC, Kim DW, Spira AI, Gomez JE, et al
    Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
    Nat Med. 2023 Sep 14. doi: 10.1038/s41591-023-02554.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum